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Treatments for obesity have been shown to reduce pain secondary to weight loss. Intestinal microbiota, as an endogenous factor,
influences obesity and pain sensitivity but the effect of oral probiotic supplementation on musculoskeletal pain perception has
not been studied systematically. The present study examined the effect of a single daily oral dose (1 × 109 CFU) of probiotics
(Lactobacillus rhamnosus PB01, DSM14870) supplement onmechanical pain thresholds in behaving diet-induced obese (DIO)mice
and their normal weight (NW) controls. The mice (𝑁 = 24, 6-week-old male) were randomly divided into four groups on either
standard or high fat diet with and without probiotic supplementation. Both DIO and NW groups with probiotic supplementation
maintained an insignificant weight gain while the control groups gained significant weight (𝑃 < 0.05). Similarly, both DIO andNW
probiotics supplemented groups demonstrated a significantly (𝑃 < 0.05) lower sensitivity to mechanical stimulation compared to
their corresponding control.The results of this study suggest a protective effect of probiotics on nociception circuits, which propose
a direct result of the weight reduction or an indirect result of anti-inflammatory properties of the probiotics. Deciphering the exact
underlying mechanism of the weight loss and lowering nociception effect of the probiotic applied in this study require further
investigation.
1. Introduction
Physiological pain plays a life-essential protective role, while
acute or chronic pathological pain indicates a medical prob-
lem that needs treatment and imposes a medical challenge
[1].
Pain perception is a complex process including neu-
ronal, nonneuronal, and cognitive processes modulated by
peripheral and central factors. Neurotransmitters, immune
cells, and hormones have been demonstrated to contribute
in pathogenesis of chronic pain [2]. Several biological and
psychological factors may interfere with perception of pain.
To mention a few, gender, depression, or genetic factors have
been shown to alter pain perception both in humans and
animals [3–5].
Since pain is a subjective concept and pain measurement
is challenging, it is usually measured under controlled con-
ditions, by responses to experimental stimuli as applied by
mechanical, thermal, electrical, and chemical stimuli [6].
Pressure pain threshold (PPT) has been identified as a
reliable and easy biomarker in multiple clinical pain states
[7, 8]. Rodent withdrawal reflex to pressure application upon
sensation of pain is interpreted as similar to PPT assessments
in humans.
Pain threshold is influenced by several factors, including
obesity, which alters adipose tissue metabolic and endocrine
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functions leading to alterations in systemic physiology
including an increased release of fatty acids, hormones, and
proinflammatorymolecules that contribute to obesity associ-
ated complications [9]. Several studies have shown that pain
sensation or threshold to painful stimuli can change due to a
state of obesity but controversial results exist [10–14]. Some
clinical studies have demonstrated a higher pressure pain
threshold in obese compared to nonobese humans patients
[11, 14]. Other studies have demonstrated that obese humans
and rats are more sensitive to pain stimuli than normal
weighted ones [15, 16]. Controversies might be due to several
factors, including ignorance of confounding variables such as
gender, age, socioeconomic factors, and comorbidities such
as diabetes, hypertension and chronic pain, methodological
differences, type of stimuli, sex, and age. In development
of obesity, intestinal microbiota has been considered as an
essential factor [5].
Previous studies have demonstrated a relationship
between intestinal microbiota and diseases including pain
disorders [17–20] with probiotics having a positive effect.
The possible beneficial role of probiotic supplementa-
tion on management of chronic musculoskeletal pain is
in its infancy and requires further investigation. To study
the confounding factors under well-controlled conditions,
experimental models in animals and humans are superior
to patient studies. In particular, rodent behavioral models
have been important tools for advancing our understanding
of the physiology underlying nociception and pain [3].
Diet-induced obese (DIO) models in mice can assist in
investigations deciphering the etiology of human obesity
since they closely mimic the result of the high fat/high
density foods in modern societies during the past decades
[21].
In this study we seek to address if probiotic supple-
ments can potentially overcome the deleterious effects of
obesity and reduce pain sensitivity by assessing the effect of
Lactobacillus rhamnosus (PB01, DSM 14870) supplement on
PPT in DIO mice. The results of this study would poten-
tially prove beneficial in treatment strategies and predictive
algorithm in conditions with existence of both obesity and
pain.
2. Materials and Methods
Animal experiments in this study were carried out in accor-
dance with the Guidelines for Animal Experimentation and
Approval of “The Danish Animal Experiments Inspectorate”
number 2014-15-0201-00026.
2.1. Animals. Twenty-four, 6-week-old male C57BL/6NTac
mice were acquired (Taconic, Denmark) and housed in a
room at 22∘C to 24∘C, with 60% relative humidity and 12 h
dark-light cycles (light on from 0800 to 2000 h). Mice were
allowed two weeks of adaptation and free access to their
respective diets and tap water ad libitum during the study
period.
2.2. Study Design
Phase I. Following adaptation, the mice were randomly
divided into two groups and fed on standard diet as normal
weight (NW) models while the other group were fed on
an industry-standard high fat (60%) research rodent diet
(D12492, ResearchDiets Inc., USA) to create the diet-induced
obesity (DIO) models.
Phase II. Four weeks after feeding on the standard or fat diet,
each group was divided into two subgroups continuing the
previous diet with or without probiotic supplements creating
the following four diet groups: normal diet (ND); normal diet
+ probiotic supplement (NDPR); fat diet (FD); and fat diet +
probiotic supplement (FDPR).
2.3. Probiotics. Lactobacillus rhamnosus PB01, DSM 14870,
was provided in the form of Lyophilized powder by Bifodan
A/S (Hundested, Denmark). Based on the product infor-
mation from the manufacturer (Bifodan A/S, Copenhagen,
Denmark), the strain PB01 had been genetically charac-
terized employing two biomolecular techniques. Species-
level identification, achieved by means of 16S rRNA gene
sequencing, demonstrated that PB01 belonged to the species
Lactobacillus rhamnosus. Pulsed Field Gel Electrophoresis
(PFGE), employed for strain typing, enabled obtaining a
strain specificmacrorestriction pattern. Previous studies have
reported the positive effect of L. rhamnosus PB01 vaginal
administration (ECOVAG) in the treatment of vaginosis
[22]. The same strain was offered to us by Bifodan A/S
(Hundsted, Denmark) and suggested (based on unpublished
preliminary studies) to also have positive beneficial effects
while administered orally.
Aliquots providing 1 × 109 CFU per mouse were prepared
(based onmanufactures guidelines) and stored at −20∘Cuntil
administration. Shortly before use, the prepared probiotic
aliquots were diluted in normal saline (0.25mL per mouse)
at room temperature as vehicle and administered orally to the
NDPR and FDPR groups.
The ND and FD groups received oral administration of
normal saline without probiotics. This process was repeated
once every day during phase II (second 4 weeks) of the
study. Probiotic administrationwas performedusing a gavage
needle to ascertain the presence of the probiotics in the
gastrointestinal tract.
2.4. Pressure Pain Sensitivity. Sensitivity to mechanical stim-
ulation, as a translational biomarker of pain sensitivity, was
assessed by the electronic Von Frey (Bioseb, France).This test
evaluates how soon a withdrawal of the paw will occur due
to a standard mechanical pressure (pressure pain threshold,
PPT, in grams). The more sensitive it is to pain, the faster
the withdrawal reaction would be detected. The mice were
weighed using a digital scale and the Von Frey test was
performed once every two weeks 3 times on all mice. Mice
were placed in an acrylic box restrainer (15 × 15 cm) with
a metal mesh floor (5 × 5mm square openings) to prevent
extra movement while having enough space to show reaction












































Figure 1: The abilities of L. rhamnosus PB01, DSM 14870, to reduce body weight (a) and increase pressure pain threshold (b) in mice fed
normal diet (ND), high fat diet (FD), normal diet with probiotics (NDPR), and fat diet with probiotics (FDPR) during 8 weeks. Data are
means (𝑛 = 6) and whiskers indicate SD (standard deviation).
to mechanical stimulation. A filament (0.1–10𝜇L pipette tip)
attached to the sensor of the Von Frey device was applied
with a steadily increasing pressure to the plantar surface
of the mouse’s hind-paw until withdrawal occurred. The
amount of pressure (g) at the time of hind-paw retraction
was recorded by the Von Frey device. Averages of three
consecutive readings (with 3-minute intervals) from the same
hind paw were recorded for further statistical analysis.
2.5. ELISA Tests. At baseline and the end of weeks 4 and 8,
blood sampleswere collected from the facial vein of conscious
mice [23]. Blood serum was obtained after centrifugation
(500 g for 10min at 4∘C) and stored at −20∘C until being
used to assess blood lipid profiles (total cholesterol (TC), high
density lipoprotein (HDL), low/very low density lipoprotein
(LDL/VLDL), and cholesterol) using a commercially avail-
able ELISA assay kit (ab65390, ABCAM, UK) according to
the manufacturer’s directions.
2.6. Statistical Analysis. Data are shown as means ± standard
deviation (SD). Repeated measures ANOVA was used to
compare differences in pain sensitivity and weight between
groups and over time points. Bonferroni post hoc test was
used for pair-wise comparison wherever ANOVA yielded
a statistical significant difference. Lipid profile parameters
(TC, HDL, and LDL/VLDL) were compared by one way
ANOVA. A 𝑃 value less than 0.05 (𝑃 < 0.05) in these
analyses was considered significant unless otherwise stated.
The “IBM SPSS Statistics” version 23 was used to perform
the mentioned statistical analysis
3. Results
3.1. Probiotics Supplementation Effects on Body Weight. As
expected, all groups demonstrated a rising trend throughout
the study period. However, the FD group, which were on a
high fat diet, gained more weight compared to the ND and
resulting in a significant weight difference (𝑃 < 0.01) at week
4.
After week 4, bothND and FD groupsmaintained a rising
trend in the weight, whereas the groups which received the
probiotic supplement maintained a stable weight with no
significant change up to week 8 (Figure 1(a)).
The stable weight of the FDPR and the rising trend in the
FD group led to a nonsignificant difference at week 6 (𝑃 =
0.08) and continued to a significant difference at week 8 (𝑃 <
0.002).
The NDPR group maintained a stable weight after the
start of probiotic supplementation at week 4 whereas the ND
group remained stable until week 8 (Figure 1(a)).
3.2. Probiotics Supplementation Effects on Pressure Pain
Threshold. The results demonstrate striking changes in the
pain pressure threshold (PPT) values in both NW and
DIO mice after 4 weeks of the probiotic supplementation
(Figure 1(b)).
At the start of the study (baseline) PPT ranged between
15 and 17.7 g. A slight increase in the PPT was observed
during the first 2 weeks of the study with each group being
maintained on their corresponding diet (normal or fat diet)
with no significant difference (Figure 1(b)).
However, a clear significant (𝑃 < 0.01) difference was
observed between the groups maintained on normal and fat
diet at week 4 (Figure 1(b)).
The FD group continued the decreasing trend in (PPT)
until week 8, whereas the FDPR group demonstrated an
increasing PPT (lower pain sensitivity) after the start of
probiotic supplementation (from week 4 to week 8) reaching
a significant (𝑃 < 0.01) difference in PPT compared to the
FD group on week 8 (Figure 1(b)).
The ND group demonstrated a rise in the PPT between
weeks 4 and 6 changing to a decreasing trend from weeks 6
to 8 (Figure 1(b)).
The NDPR group also demonstrated an increasing PPT
(lower pain sensitivity) after the start of probiotic supple-
mentation (from week 4 to week 8) reaching a significant
(𝑃 < 0.01) difference in PPT compared to the ND group at
week 8 (Figure 1(b)).
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Table 1: Lipid profiles in mice fed normal diet (ND), high fat diet (FD), normal diet with probiotics (NDPR), and fat diet with probiotics
(FDPR) at the start of the study (base) and at 4 and 8 weeks into the study (4W and 8W). Provided values are the mean ± standard deviation.
Similar superscripted letters demonstrate pairwise significant (𝑃 < 0.05) differences.
Lipid profile parameters Base ND 4W ND 8W NDPR 8W FD 4W FD 8W FDPR 8W
LDL/VLDL 0.17 ± 0.03 0.17 ± 0.02 0.18 ± 0.02b 0.14 ± 0.02c 0.19 ± 0.06 0.32 ± 0.05a,b 0.21 ± 0.03a,c
HDL 0.44 ± 0.06 0.35 ± 0.05 0.66 ± 0.16c 0.56 ± 0.05a,b 1.17 ± 0.27 1.42 ± 0.24b 1.46 ± 0.46a,c
Total cholesterol 0.72 ± 0.08 0.88 ± 0.20 1.05 ± 0.15a,d 0.96 ± 0.09b,c 1.57 ± 0.22 1.73 ± 0.01a,b,e 1.56 ± 0.07c,d,e
At the end of this study, week 8, the results of PPT were
significantly (𝑃 < 0.01) different between all groups with
the NDPR demonstrating the highest PPT in the FDPR,
ND, and FD groups, respectively (22.17, 16, 12, and 7.83 (g))
(Figure 1(b)).
3.3. Probiotics Supplementation Effects on Lipid Profiles.
The serum lipid profiles (serum total cholesterol, LDL-
cholesterol, and HDL-cholesterol) of the mice at the start of
the study (base) and after 4 and 8 weeks of the respective diet
with orwithout probiotic supplement are presented inTable 1.
4. Discussion and Conclusion
The novelty and main purpose of this study were to inves-
tigate the potential of the probiotic Lactobacillus rhamnosus
supplementation on weight gain and pain sensitivity by
assessing pain thresholds in DIO mice versus controls.
4.1. Effect of Probiotics on Body Weight. Our results demon-
strated that DIO group had a higher body weigh compared
with NW. Both of the normal and fat diet groups receiving
probiotic supplements maintained a stable weight whereas
their corresponding diet groupwithout probiotic supplemen-
tation continued to gain weight until the end of study at
week 8. This observation supported the report by Sanchez et
al. that the probiotics (L. rhamnosus CGMCC1.3724) could
lower body weight [24].
The gut’s microbial community is recognized as one
of the particular factors related to obesity and metabolic
disorders [25–27]. Many studies have demonstrated various
mechanisms of antiobesity ofLactobacillus, such as regulation
of lipid and glucose metabolism [26, 28], production of
conjugated linoleic acid [29, 30], reduction of adipocyte size
and increase of numbers of small adipocytes in white adipose
tissue [31, 32], and regulation of leptin [33].
4.2. Effect of Probiotics on Serum Lipid Profiles. Our study
demonstrated that total cholesterol levels and LDL/VLDL
levels had a rising trend over time in both normal and fat
diet groups. Both of the NW and DIO groups receiving
probiotic supplements demonstrated lower total cholesterol
and LDL/VLDL levels while their corresponding diet group
without probiotic supplements showed higher total choles-
terol and LDL/VLDL levels throughout the study. Obesity
is generally accompanied by an increased concentration of
serum total cholesterol [34]. Numerous mechanisms have
been suggested for the hypolipidemic activity of probiotics
including “deconjugating bile acids through bile salt hydro-
lase catalysis, uptake and assimilation of cholesterol for stabi-
lization of the cell membrane and binding cholesterol to cell
walls by probiotics in the intestine, conversion of cholesterol
into coprostanol, inhibition of hepatic cholesterol synthesis
by short chain fatty acids such as propionate produced by
probiotic bacteria and/or redistribution of cholesterol from
plasma to the liver [35]”. Still, many of these proposed
mechanisms and experimental evidence specifically targeting
cholesterol-lowering effects of probiotics remain controver-
sial [36].
Many studies have reported the hypolipidemic effect of
several probiotics strains in animals which is also observed
and in line with the results of this study [37–44].
Several studies in humans also confirm the cholesterol-
lowering effects of probiotics [45–47] whereas a few studies
have reported no contribution of probiotics to any lipid
profile changes [48–51]. The controversial results may be
due to differences in strains used and the delivery method
where the matrix (as a probiotic carrier) may influence the
cholesterol-lowering effect of probiotics [36].
4.3. Pressure Pain Threshold in DIO and NW Mice. Our
results demonstrated that DIO group had a lower mechanical
pain pressure threshold (higher pain sensitivity) compared
with groups treated with the normal diet.
Results from this study are in line with the findings of sev-
eral previous reports generally demonstrating a significantly
higher pain sensitivity in obese humans [15, 52] and diabetic
obese rats [53].
Obese rats receiving intradermal carrageenan injection
in the paw were also shown to exhibit greater peripheral
inflammation and hyperalgesia compared to lean rats [54]
suggesting an inflammatory response potentiated by obesity
or various neurophysiological changes as a result of weight
gain contributing to the change in nociceptive processing
[55].
It has been reported that obesity share a low grade chronic
inflammatory state [56]. Cani et al. also showed that high fat
feeding induced a low tone inflammation which originates
from the intestinal absorption of the lipopolysaccharide
(LPS) [57].
Guilherme et al. have reported that hypertrophy of
adipocytes due to increased triglycerides uptake to these cells
could result in the induction of a chronic inflammatory state
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by the recruitment of macrophages within the adipose tissue
[58].
de Goeij et al. provide additional evidence that sys-
temic inflammation accompanied by changes in pain percep-
tion could result in “inflammation-induced increased pain
sensitivity”[59].
Other studies evaluating experimentally induced pain
in obese and lean human and animal models in laboratory
settings have resulted in somewhat controversial results.
Some studies reported increased pain response to thermal
noxious stimuli and pressure in obese rats [16, 53] while
others show no difference in pain behaviors in response
to pressure or thermal stimuli [55] or reduced hyperalgesia
response [60].
Earlier studies have demonstrated that obese people
exhibited decreased pain threshold to mechanical stimuli
[15]. Inconsistent results from several studies across body
parts in humans also suggest that the reduced pain threshold
in obesity may not be seen in all body areas [55].
4.4. Effect of Probiotics on Pressure Pain Threshold. In this
study a major increase in pressure pain threshold rates
(lower sensitivity) was observed in groups with probiotic
consumption compared with the groups with no probiotic
supplement. Several lines of research have declared that
probiotics exhibit powerful anti-inflammatory properties [61,
62]. Other previous studies have indicated a dependency on
the intestinal microflora and on the dysregulated immune
response to their antigenic structures for the development
of gut associated inflammatory conditions, ranging from
allergies to autoimmune and inflammatory diseases [63].
Yokokura [64] also reported increased levels of the inflam-
matory immune response associated cytokine IL-2, with
the oral application of “L. casei strain Shirota.” This anti-
inflammatory effect could also explain the reduced pain
sensitivity in the test groups with probiotic supplementation
in this study. However, other unknownmechanismsmight be
involved.
Regardless of the underlying mechanism, probiotics can
be suggested as candidates of a novel strategy for weight and
pain control in accordance with the management of pain in
cases of obesity or normal weight. Translation of this result in
humans can potentially suggest a novel therapeutic strategy
in pain management of obese or normal weight individuals.
In conclusion this study demonstrated the potential
of Lactobacillus rhamnosus (PB01, DSM 14870) probiotic
supplementation as a weight and pain sensitivity regulator
in diet-induced obesity mice model that could indirectly
be associated with the induced weight reduction or anti-
inflammatory properties of the probiotic.
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